Ocugen Inc. (OCGN)
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders.
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript
Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript
Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments
Ocugen remains a "Buy", driven by pivotal phase 2/3 GARDian3 trial progress for OCU410ST in Stargardt Disease. FDA and EMA regulatory alignment enables a single U.S. trial to support both BLA and MAA filings for OCU410ST, expediting potential approvals. Interim data from GARDian3 is expected by mid-2026, with possible BLA submission for OCU410ST in 2027 if results are positive.
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript
Ocugen, Inc. ( OCGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Boris Peaker Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Daniil Gataulin - Chardan Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to Ocugen's Third Quarter 2025 Financial Results and Business Update.
Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago.
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
